Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
Clinical trial NCT06015230 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06015230
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-08
- Primary completion
- 2028-06-10
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.